Polymorphisms influencing prostate-specific antigen concentration may bias genome-wide association studies on prostate cancer

Paul J. Dluzniewski, Jianfeng Xu, Ingo Ruczinski, William B Isaacs, Elizabeth A Platz

Research output: Contribution to journalArticle

Abstract

Background: Genome-wide association studies (GWAS) have produced weak (OR = 1.1-1.5) but significant associations between single nucleotide polymorphisms (SNPs) and prostate cancer. However, these associations may be explained by detection bias caused by SNPs influencing PSA concentration. Thus, in a simulation study, we quantified the extent of bias in the association between a SNP and prostate cancer when the SNP influences PSA concentration. Methods: We generated 2,000 replicate cohorts of 20,000 men using real-world estimates of prostate cancer risk, prevalence of carrying ≥1 minor allele, PSA concentration, and the influence of a SNP on PSA concentration. We modeled risk ratios (RR) of 1.00, 1.25, and 1.50 for the association between carrying ≥1 minor allele and prostate cancer. We calculated mean betas from the replicate cohorts and quantified bias under each scenario. Results: Assuming no association between a SNP and prostate cancer, the estimated mean bias in betas ranged from 0.02 to 0.10 for ln PSA being 0.05 to 0.20 ng/mL higher in minor allele carriers; the mean biased RRs ranged from 1.03 to 1.11. Assuming true RRs = 1.25 and 1.50, the biased RRs were as large as 1.39 and 1.67, respectively. Conclusion: Estimates of the association between SNPs and prostate cancer can be biased to the magnitude observed in published GWAS, possibly resulting in type I error. However, large associations (RR > 1.10) may not fully be explained by this bias. Impact: The influence of SNPs on PSA concentration should be considered when interpreting results from GWAS on prostate cancer.

Original languageEnglish (US)
Pages (from-to)88-93
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Genome-Wide Association Study
Prostate-Specific Antigen
Single Nucleotide Polymorphism
Prostatic Neoplasms
Alleles
Odds Ratio

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

@article{73d8d97bc73e46b0abf147e3440e4a36,
title = "Polymorphisms influencing prostate-specific antigen concentration may bias genome-wide association studies on prostate cancer",
abstract = "Background: Genome-wide association studies (GWAS) have produced weak (OR = 1.1-1.5) but significant associations between single nucleotide polymorphisms (SNPs) and prostate cancer. However, these associations may be explained by detection bias caused by SNPs influencing PSA concentration. Thus, in a simulation study, we quantified the extent of bias in the association between a SNP and prostate cancer when the SNP influences PSA concentration. Methods: We generated 2,000 replicate cohorts of 20,000 men using real-world estimates of prostate cancer risk, prevalence of carrying ≥1 minor allele, PSA concentration, and the influence of a SNP on PSA concentration. We modeled risk ratios (RR) of 1.00, 1.25, and 1.50 for the association between carrying ≥1 minor allele and prostate cancer. We calculated mean betas from the replicate cohorts and quantified bias under each scenario. Results: Assuming no association between a SNP and prostate cancer, the estimated mean bias in betas ranged from 0.02 to 0.10 for ln PSA being 0.05 to 0.20 ng/mL higher in minor allele carriers; the mean biased RRs ranged from 1.03 to 1.11. Assuming true RRs = 1.25 and 1.50, the biased RRs were as large as 1.39 and 1.67, respectively. Conclusion: Estimates of the association between SNPs and prostate cancer can be biased to the magnitude observed in published GWAS, possibly resulting in type I error. However, large associations (RR > 1.10) may not fully be explained by this bias. Impact: The influence of SNPs on PSA concentration should be considered when interpreting results from GWAS on prostate cancer.",
author = "Dluzniewski, {Paul J.} and Jianfeng Xu and Ingo Ruczinski and Isaacs, {William B} and Platz, {Elizabeth A}",
year = "2015",
month = "1",
day = "1",
doi = "10.1158/1055-9965.EPI-14-0863",
language = "English (US)",
volume = "24",
pages = "88--93",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Polymorphisms influencing prostate-specific antigen concentration may bias genome-wide association studies on prostate cancer

AU - Dluzniewski, Paul J.

AU - Xu, Jianfeng

AU - Ruczinski, Ingo

AU - Isaacs, William B

AU - Platz, Elizabeth A

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Genome-wide association studies (GWAS) have produced weak (OR = 1.1-1.5) but significant associations between single nucleotide polymorphisms (SNPs) and prostate cancer. However, these associations may be explained by detection bias caused by SNPs influencing PSA concentration. Thus, in a simulation study, we quantified the extent of bias in the association between a SNP and prostate cancer when the SNP influences PSA concentration. Methods: We generated 2,000 replicate cohorts of 20,000 men using real-world estimates of prostate cancer risk, prevalence of carrying ≥1 minor allele, PSA concentration, and the influence of a SNP on PSA concentration. We modeled risk ratios (RR) of 1.00, 1.25, and 1.50 for the association between carrying ≥1 minor allele and prostate cancer. We calculated mean betas from the replicate cohorts and quantified bias under each scenario. Results: Assuming no association between a SNP and prostate cancer, the estimated mean bias in betas ranged from 0.02 to 0.10 for ln PSA being 0.05 to 0.20 ng/mL higher in minor allele carriers; the mean biased RRs ranged from 1.03 to 1.11. Assuming true RRs = 1.25 and 1.50, the biased RRs were as large as 1.39 and 1.67, respectively. Conclusion: Estimates of the association between SNPs and prostate cancer can be biased to the magnitude observed in published GWAS, possibly resulting in type I error. However, large associations (RR > 1.10) may not fully be explained by this bias. Impact: The influence of SNPs on PSA concentration should be considered when interpreting results from GWAS on prostate cancer.

AB - Background: Genome-wide association studies (GWAS) have produced weak (OR = 1.1-1.5) but significant associations between single nucleotide polymorphisms (SNPs) and prostate cancer. However, these associations may be explained by detection bias caused by SNPs influencing PSA concentration. Thus, in a simulation study, we quantified the extent of bias in the association between a SNP and prostate cancer when the SNP influences PSA concentration. Methods: We generated 2,000 replicate cohorts of 20,000 men using real-world estimates of prostate cancer risk, prevalence of carrying ≥1 minor allele, PSA concentration, and the influence of a SNP on PSA concentration. We modeled risk ratios (RR) of 1.00, 1.25, and 1.50 for the association between carrying ≥1 minor allele and prostate cancer. We calculated mean betas from the replicate cohorts and quantified bias under each scenario. Results: Assuming no association between a SNP and prostate cancer, the estimated mean bias in betas ranged from 0.02 to 0.10 for ln PSA being 0.05 to 0.20 ng/mL higher in minor allele carriers; the mean biased RRs ranged from 1.03 to 1.11. Assuming true RRs = 1.25 and 1.50, the biased RRs were as large as 1.39 and 1.67, respectively. Conclusion: Estimates of the association between SNPs and prostate cancer can be biased to the magnitude observed in published GWAS, possibly resulting in type I error. However, large associations (RR > 1.10) may not fully be explained by this bias. Impact: The influence of SNPs on PSA concentration should be considered when interpreting results from GWAS on prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84921027475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921027475&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-14-0863

DO - 10.1158/1055-9965.EPI-14-0863

M3 - Article

VL - 24

SP - 88

EP - 93

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 1

ER -